Pharmaceutical Analysis & Statistics, August 2014

Talk to Amrita

+1 718 303 2019

Publishers

  • All
    • Global Data

All regions

You might be interested in: therapeutics, drug, cancer, more »

1-30 of about 8 700 reports

Purchase Reports From Reputable Market Research Publishers

PharmaPoint: Major Depressive Disorder - 5EU Drug Forecast and Market Analysis to 2023

PharmaPoint: Major Depressive Disorder - 5EU Drug Forecast and Market Analysis to 2023

  • $ 6 995
  • Industry report
  • May 2014
  • by Global Data

PharmaPoint: Major Depressive Disorder - 5EU Drug Forecast and Market Analysis to 2023 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is ...

  • Industries : Pathology
  • Countries : Spain, Italy, France, Germany, United Kingdom, Europe, World
OpportunityAnalyzer: Dengue Vaccines - Opportunity Analysis and Forecasts to 2020

OpportunityAnalyzer: Dengue Vaccines - Opportunity Analysis and Forecasts to 2020

  • $ 5 995
  • Industry report
  • July 2014
  • by Global Data

OpportunityAnalyzer: Dengue Vaccines - Opportunity Analysis and Forecasts to 2020 Summary Dengue is a febrile illness caused by the dengue virus (DENV), a single-stranded flavivirus most commonly transmitted ...

  • Industries : Drug and Medication
  • Countries : Singapore, Brazil, India, Mexico, Thailand, World
OpportunityAnalyzer: Cystic Fibrosis - Opportunity Analysis and Forecasts to 2018 - Event-Driven Update

OpportunityAnalyzer: Cystic Fibrosis - Opportunity Analysis and Forecasts to 2018 - Event-Driven Update

  • $ 5 995
  • Industry report
  • July 2014
  • by Global Data

OpportunityAnalyzer: Cystic Fibrosis - Opportunity Analysis and Forecasts to 2018 - Event-Driven Update Summary Cystic Fibrosis (CF) is an autosomal recessive disease characterized by the secretion of ...

  • Industries : Pathology
OpportunityAnalyzer: Chronic Lymphocytic Leukemia - Opportunity Analysis and Forecasts to 2018

OpportunityAnalyzer: Chronic Lymphocytic Leukemia - Opportunity Analysis and Forecasts to 2018

  • $ 5 995
  • Industry report
  • June 2014
  • by Global Data

OpportunityAnalyzer: Chronic Lymphocytic Leukemia - Opportunity Analysis and Forecasts to 2018 Summary Chronic lymphocytic leukemia (CLL), the most common form of adult leukemia, is caused by the uncontrolled ...

  • Industries : Pathology
OpportunityAnalyzer: Acne Vulgaris - Opportunity Analysis and Forecasts to 2018

OpportunityAnalyzer: Acne Vulgaris - Opportunity Analysis and Forecasts to 2018

  • $ 5 995
  • Industry report
  • June 2014
  • by Global Data

OpportunityAnalyzer: Acne Vulgaris - Opportunity Analysis and Forecasts to 2018 Summary Despite its considerable patient population, the acne market has been overlooked and remained stagnant for the last ...

  • Industries : Drug and Medication
  • Countries : United States
OpportunityAnalyzer: Amyotrophic Lateral Sclerosis (ALS) - Opportunity Analysis and Forecasts to 2018

OpportunityAnalyzer: Amyotrophic Lateral Sclerosis (ALS) - Opportunity Analysis and Forecasts to 2018

  • $ 5 995
  • Industry report
  • June 2014
  • by Global Data

OpportunityAnalyzer: Amyotrophic Lateral Sclerosis (ALS) - Opportunity Analysis and Forecasts to 2018 Summary Amyotrophic lateral sclerosis (ALS) is a rare, but fatal, motor neuron disease (MND) characterized ...

  • Industries : Pathology
  • Countries : World, United States, Japan
PharmaPoint: Major Depressive Disorder - US Drug Forecast and Market Analysis to 2023

PharmaPoint: Major Depressive Disorder - US Drug Forecast and Market Analysis to 2023

  • $ 4 995
  • Industry report
  • May 2014
  • by Global Data

PharmaPoint: Major Depressive Disorder - US Drug Forecast and Market Analysis to 2023 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is ...

  • Industries : Pathology
  • Countries : United States
PharmaPoint: Major Depressive Disorder - Japan Drug Forecast and Market Analysis to 2023

PharmaPoint: Major Depressive Disorder - Japan Drug Forecast and Market Analysis to 2023

  • $ 4 995
  • Industry report
  • May 2014
  • by Global Data

PharmaPoint: Major Depressive Disorder - Japan Drug Forecast and Market Analysis to 2023 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market ...

  • Industries : Pathology
  • Countries : Japan
PharmaPoint: Major Depressive Disorder - Australia Drug Forecast and Market Analysis to 2023

PharmaPoint: Major Depressive Disorder - Australia Drug Forecast and Market Analysis to 2023

  • $ 4 995
  • Industry report
  • May 2014
  • by Global Data

PharmaPoint: Major Depressive Disorder - Australia Drug Forecast and Market Analysis to 2023 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market ...

  • Industries : Pathology
  • Countries : Australia
EpiCast Report: Acute Coronary Syndrome (ACS) - Epidemiology Forecast to 2023

EpiCast Report: Acute Coronary Syndrome (ACS) - Epidemiology Forecast to 2023

  • $ 3 995
  • Industry report
  • July 2014
  • by Global Data

EpiCast Report: Acute Coronary Syndrome (ACS) - Epidemiology Forecast to 2023 Summary Acute coronary syndrome (ACS) is a serious cardiovascular disease associated with high healthcare costs, frequent recurrences ...

  • Industries : Pathology
  • Countries : Germany, World, United States, Spain, United Kingdom, Italy, France, Japan
MediPoint: Companion Diagnostic Tests in Oncology - Current and Future Players

MediPoint: Companion Diagnostic Tests in Oncology - Current and Future Players

  • $ 3 500
  • Industry report
  • May 2014
  • by Global Data

MediPoint: Companion Diagnostic Tests in Oncology - Current and Future Players Summary A companion diagnostic test is defined as an in vitro diagnostic device or an imaging tool whose use allows the safe ...

  • Industries : Pathology
Seroquel XR (Major Depressive Disorder) - Forecast and Market Analysis to 2023

Seroquel XR (Major Depressive Disorder) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • May 2014
  • by Global Data

Seroquel XR (Major Depressive Disorder) - Forecast and Market Analysis to 2023 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded ...

  • Industries : Pathology
  • Countries : Australia
Brexpiprazole (Major Depressive Disorder) - Forecast and Market Analysis to 2023

Brexpiprazole (Major Depressive Disorder) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • May 2014
  • by Global Data

Brexpiprazole (Major Depressive Disorder) - Forecast and Market Analysis to 2023 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded ...

  • Industries : Pathology
  • Countries : Australia, World, Spain, Italy, France, Germany, Japan, Europe, United States, United Kingdom, Oceania
Cariprazine (Major Depressive Disorder) - Forecast and Market Analysis to 2023

Cariprazine (Major Depressive Disorder) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • May 2014
  • by Global Data

Cariprazine (Major Depressive Disorder) - Forecast and Market Analysis to 2023 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded ...

  • Industries : Pathology
  • Countries : Australia, World, Spain, Italy, France, Germany, Japan, United States, United Kingdom, Europe, Oceania
ALKS-5461 (Major Depressive Disorder) - Forecast and Market Analysis to 2023

ALKS-5461 (Major Depressive Disorder) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • May 2014
  • by Global Data

ALKS-5461 (Major Depressive Disorder) - Forecast and Market Analysis to 2023 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded ...

  • Industries : Pathology
  • Countries : Australia, World, Spain, Italy, France, Germany, Japan, United States, United Kingdom, Europe, Oceania
Amitifadine (Major Depressive Disorder) - Forecast and Market Analysis to 2023

Amitifadine (Major Depressive Disorder) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • May 2014
  • by Global Data

Amitifadine (Major Depressive Disorder) - Forecast and Market Analysis to 2023 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded ...

  • Industries : Pathology
  • Countries : Australia, World, Spain, Italy, France, Germany, Japan, United States, United Kingdom, Europe, Oceania
GLYX-13 (Major Depressive Disorder) - Forecast and Market Analysis to 2023

GLYX-13 (Major Depressive Disorder) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • May 2014
  • by Global Data

GLYX-13 (Major Depressive Disorder) - Forecast and Market Analysis to 2023 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded ...

  • Industries : Pathology
  • Countries : Australia, World, Spain, Italy, France, Germany, Japan, United States, United Kingdom, Europe, Oceania
Tedatioxetine (Major Depressive Disorder) - Forecast and Market Analysis to 2023

Tedatioxetine (Major Depressive Disorder) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • May 2014
  • by Global Data

Tedatioxetine (Major Depressive Disorder) - Forecast and Market Analysis to 2023 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded ...

  • Industries : Pathology
  • Countries : Australia, World, Spain, Italy, France, Germany, Japan
Lexapro (Major Depressive Disorder) - Forecast and Market Analysis to 2023

Lexapro (Major Depressive Disorder) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • May 2014
  • by Global Data

Lexapro (Major Depressive Disorder) - Forecast and Market Analysis to 2023 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded ...

  • Industries : Pathology
  • Countries : Australia, World, Spain, Italy, France, Germany, Japan, United States, United Kingdom, Europe, Oceania
ETS6103 (Major Depressive Disorder) - Forecast and Market Analysis to 2023

ETS6103 (Major Depressive Disorder) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • May 2014
  • by Global Data

ETS6103 (Major Depressive Disorder) - Forecast and Market Analysis to 2023 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded ...

  • Industries : Pathology
  • Countries : Australia, World, Spain, Italy, France, Germany, Japan, United States, United Kingdom, Europe, Oceania
Viibryd (Major Depressive Disorder) - Forecast and Market Analysis to 2023

Viibryd (Major Depressive Disorder) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • May 2014
  • by Global Data

Viibryd (Major Depressive Disorder) - Forecast and Market Analysis to 2023 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded ...

  • Industries : Pathology
  • Countries : United States, Australia, World
Effexor (Major Depressive Disorder) - Forecast and Market Analysis to 2023

Effexor (Major Depressive Disorder) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • May 2014
  • by Global Data

Effexor (Major Depressive Disorder) - Forecast and Market Analysis to 2023 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded ...

  • Industries : Pathology
  • Countries : Australia, World, United States, Spain, Italy, France, Germany, United Kingdom, Europe, Oceania
Cymbalta (Major Depressive Disorder) - Forecast and Market Analysis to 2023

Cymbalta (Major Depressive Disorder) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • May 2014
  • by Global Data

Cymbalta (Major Depressive Disorder) - Forecast and Market Analysis to 2023 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded ...

  • Industries : Pathology
  • Countries : Australia, Japan, World, Spain, Italy, France, Germany, United States, United Kingdom, Europe, Oceania
Pristiq (Major Depressive Disorder) - Forecast and Market Analysis to 2023

Pristiq (Major Depressive Disorder) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • May 2014
  • by Global Data

Pristiq (Major Depressive Disorder) - Forecast and Market Analysis to 2023 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded ...

  • Industries : Pathology
  • Countries : Australia
Fetzima (Major Depressive Disorder) - Forecast and Market Analysis to 2023

Fetzima (Major Depressive Disorder) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • May 2014
  • by Global Data

Fetzima (Major Depressive Disorder) - Forecast and Market Analysis to 2023 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded ...

  • Industries : Pathology
  • Countries : United States, World, Australia, Canada
Savella (Major Depressive Disorder) - Forecast and Market Analysis to 2023

Savella (Major Depressive Disorder) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • May 2014
  • by Global Data

Savella (Major Depressive Disorder) - Forecast and Market Analysis to 2023 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded ...

  • Industries : Pathology
Brintellix (Major Depressive Disorder) - Forecast and Market Analysis to 2023

Brintellix (Major Depressive Disorder) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • May 2014
  • by Global Data

Brintellix (Major Depressive Disorder) - Forecast and Market Analysis to 2023 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded ...

  • Industries : Pathology
  • Countries : Australia, World, Spain, Italy, France, Germany, Japan, Europe, United States, United Kingdom, Oceania
Abilify (Major Depressive Disorder) - Forecast and Market Analysis to 2023

Abilify (Major Depressive Disorder) - Forecast and Market Analysis to 2023

  • $ 3 495
  • Industry report
  • May 2014
  • by Global Data

Abilify (Major Depressive Disorder) - Forecast and Market Analysis to 2023 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. The MDD market is a crowded ...

  • Industries : Pathology
  • Countries : Australia, Japan, World, Spain, Italy, France, Germany, United States, United Kingdom, Europe, Oceania
PharmaPoint: Major Depressive Disorder - Current and Future Players

PharmaPoint: Major Depressive Disorder - Current and Future Players

  • $ 2 995
  • Industry report
  • May 2014
  • by Global Data

PharmaPoint: Major Depressive Disorder - Current and Future Players Summary GlobalData has released its pharma report, “PharmaPoint: Major Depressive Disorder - Current and Future Players”. The report ...

  • Industries : Pathology
  • Countries : World, Australia
Atrial Septal Defect Global Clinical Trials Review, H2, 2014

Atrial Septal Defect Global Clinical Trials Review, H2, 2014

  • $ 2 500
  • Industry report
  • August 2014
  • by Global Data

Atrial Septal Defect Global Clinical Trials Review, H2, 2014 Summary GlobalData's clinical trial report, “Atrial Septal Defect Global Clinical Trials Review, H2, 2014" provides data on the Atrial Septal ...

  • Industries : Drug Discovery and Development
  • Countries : World
About 55 000 reports

Download Unlimited Documents from Trusted Public Sources

Health Facility Industry in Ethiopia

  • Delay for first Consultation and Associated Factors among Tuberc...
  • August 2014
    6 pages
  • Health Facility  

  • Ethiopia  

View report >

About 200 Companies

Read our Company Profiles

GlaxoSmithKline P.L.C.

United States

Pfizer Inc.

United States

GlaxoSmithKline PLC

United Kingdom

Novartis Inc.

Switzerland

Johnson and Johnson

United States

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.